Back to Screener

Healthcare

LeMaitre Vascular, Inc.(LMAT)

Live Price

Offline

$94.18

+2.09% today

1Y Change

+11.13%

Window

Jun 25, 2025 โ†’ Jun 18, 2026

Market Cap
$2.54B
Revenue Growth
+13.5%
EPS Growth
+30.1%
Dividend Yield
0.8%

Coverage: 247 bars ยท Jun 25, 2025 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

LeMaitre Vascular, Inc. (LMAT) is a Healthcare stock with a market cap of $2.54B and listed on NASDAQ. The stock last traded around $94.17 and up 11.1% across the available one-year price window (Jun 25, 2025 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of +13.5%, EPS growth of +30.1%, a dividend yield of 0.8%. What stands out right now is revenue +13.5%, EPS +30.1%, free cash flow +100.4% with operating margin 27.2% and ROIC 9.0%. The dividend is present but secondary, with a yield around 0.8%. Valuation already assumes a fairly strong business story at P/E 43.9 and price/sales 10.2. Stock Foundry combines LMAT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

LMAT vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

LMAT

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

LMAT Max Drawdown

-22.12%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for LMAT and SPY.

Calendar-year return history is still loading or unavailable.

Financial profile

LeMaitre Vascular, Inc. (LMAT)

Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.

Latest Revenue

โ€”

Latest Net Income

โ€”

Free Cash Flow

โ€”

Revenue Growth

+13.5%

EPS Growth

+30.1%

Gross Margin

71.5%

Net Margin

23.1%

No financial statement data available for LMAT in annual view.

Next Step

Turn financials into a decision

Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.